Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Prostate01 of saruparib plus investigator-chosen novel hormonal therapy in metastatic castration-sensitive prostate cancer
CTR20241066Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of saruparib in prostate cancer (PCa), sponsored by AstraZeneca. Started Jun 2024; status: active.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20241066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241066.